REGENXBIO Inc. Debt Securities, Available-for-sale, Allowance for Credit Loss
REGENXBIO Inc. (RGNX) had Debt Securities, Available-for-sale, Allowance for Credit Loss of $0 as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Credit Losses
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2026-03-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2025-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2025-09-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-06 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-12 |
| 2024-12-31 | $0.00 10-Q · filed 2025-11-06 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-06 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-01 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 |
| 2023-12-31 | $0.00 10-Q · filed 2024-11-06 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-02 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-03 |
| 2022-12-31 | $0.00 10-Q · filed 2023-11-08 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-03 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 |
| 2021-12-31 | $0.00 10-Q · filed 2022-11-03 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-02 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-09 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-05 |
| 2020-12-31 | $0.00 10-Q · filed 2021-11-02 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-04 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |